Osteoporosis International

, Volume 23, Issue 11, pp 2693–2701 | Cite as

Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate—Danish National Register Based Cohort Study

  • M. Pazianas
  • B. Abrahamsen
  • P. A. Eiken
  • R. Eastell
  • R. Graham G. Russell
Original Article

Abstract

Summary

In this Danish national register-based cohort study, we examined the effects of alendronate on the development of colon cancers and survival. The incidence of colon cancer and mortality rate, once colon cancer had been diagnosed, were lower in patients treated with alendronate, posing the question whether alendronate acts as chemopreventive.

Introduction

When bisphosphonates are given by mouth, around 99% remains non-absorbed in the intestine. Based on their biochemical actions, we predicted that oral bisphosphonates might prevent colon cancers.

Methods

This is a Danish national register-based cohort study. We identified 30,606 women aged 50+, mean age 71.9 years, who had not previously taken treatments for osteoporosis, who began to take alendronate in 1996–2005, and assigned 124,424 individually age- and gender-matched control subjects. The main outcome measure was colorectal cancers incidence and post-diagnosis survival in patients taking oral alendronate for osteoporosis.

Results

Cox proportional hazards analysis of death due to colon cancer showed lower risk in alendronate users, crude hazard ratio (HR) 0.69 (95% CI 0.59–0.81) with an adjusted HR of 0.62 (95% CI 0.52–0.72). The reduction in risk comprised both a lower incidence of colon cancer-adjusted HR 0.69 (95% CI 0.60–0.79) and a lower mortality once colon cancer had been diagnosed, adjusted HR 0.82 (95% CI 0.70–0.97). Weekly alendronate was associated with a greater risk reduction than daily alendronate. The main findings were unaffected by excluding patients from the analysis who had pulmonary disease, a major co-morbid condition in users of alendronate and an important cause of death.

Conclusions

The risk of overall deaths from cancer and in particular death caused by colon cancer was significantly and substantially decreased (40%) in patients treated with alendronate, with survival curves deviating progressively after 2 years. Also, the incidence of colon cancer was lower in those patients.

Keywords

Colorectal cancer Incidence Mortality Oral bisphosphonates 

Notes

Conflicts of interest

M. Pazianas: Grant/Research support from the Alliance for Better Bone Health and Warner Chilcott. B. Abrahamsen: Grant/Research support from Novartis, Nycomed, Amgen, Speakers Bureau with Merck, Eli Lilly. P. Eiken: Grant/Research support from Amgen, Speakers Bureau with Nycomed, Roche, Eli Lilly and Servier. R. Eastell: Grant/Research support from Amgen, Novartis, Procter & Gamble, Servier, Ono Pharmaceutical, GlaxoSmithKline, AstraZeneca. Speakers Bureau with Eli Lilly. R.G.G. Russell: Research support from Procter and Gamble, Sanofi-Aventis, and Warner Chilcott, Consultant/speaker and legal activities Amgen, GlaxoSmithKline, Roche, Procter and Gamble, Sanofi-Aventis, Novartis, Eli Lilly, Teva and Warner Chilcott.

References

  1. 1.
    Russell RG, Watts NB, Ebetino FH, Rogers MJ (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19:733–759PubMedCrossRefGoogle Scholar
  2. 2.
    Fritz G, Just I, Kaina B (1999) Rho GTPases are over-expressed in human tumors. Int J Cancer 81:682–687PubMedCrossRefGoogle Scholar
  3. 3.
    Clark EA, Golub TR, Lander ES, Hynes RO (2000) Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406(6795):532–535, Erratum in: Nature 2001 21;411(6840):974PubMedCrossRefGoogle Scholar
  4. 4.
    Pruitt K, Der CJ (2001) Ras and Rho regulation of the cell cycle and oncogenesis. Cancer Lett 171:1–10PubMedCrossRefGoogle Scholar
  5. 5.
    Vigil D, Cherfils J, Rossman KL, Der CJ (2010) Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nat Rev Cancer 10:842–857PubMedCrossRefGoogle Scholar
  6. 6.
    Suri S, Mönkkönen J, Taskinen M et al (2001) Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicity. Bone 29:336–343PubMedCrossRefGoogle Scholar
  7. 7.
    Sewing L, Steinberg F, Schmidt H, Göke R (2008) The bisphosphonate zoledronic acid inhibits the growth of HCT-116 colon carcinoma cells and induces tumor cell apoptosis. Apoptosis 13:782–789PubMedCrossRefGoogle Scholar
  8. 8.
    Todaro M, D'Asaro M, Caccamo N et al (2009) Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes. J Immunol 182:7287–7296PubMedCrossRefGoogle Scholar
  9. 9.
    Hosmer DW, Lemeshow S (1999) Applied survival analysis: regression modeling of time to event data, vol 6. Wiley, New YorkGoogle Scholar
  10. 10.
    Machado M, Cruz LS, Tannus G, Fonseca M (2009) Efficacy of clodronate, pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: a meta-analysis of randomized clinical trials. Clin Ther 31:962–979PubMedCrossRefGoogle Scholar
  11. 11.
    Bolland MJ, Grey AB, Gamble GD, Reid IR (2010) Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab 95(3):1174–1181PubMedCrossRefGoogle Scholar
  12. 12.
    Lyles KW, Colón-Emeric CS, Magaziner JS, For the HORIZON Recurrent Fracture Trial et al (2007) Zoledronic acid in reducing clinical fracture and mortality after hip fracture. N Engl J Med 357:nihpa40967PubMedCrossRefGoogle Scholar
  13. 13.
    Colon-Emeric CS, Mesenbrink P, Lyles KW et al (2010) Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J Bone Miner Res 25:91–97PubMedCrossRefGoogle Scholar
  14. 14.
    Sambrook PN, Cameron ID, Chen JS, March LM, Simpson JM, Cumming RG, Seibel MJ (2011) Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study. Osteoporos Int 22(9):2551–2556, Epub 2010 Oct 20PubMedCrossRefGoogle Scholar
  15. 15.
    Rennert G, Pinchev M, Rennert HS, Gruber SB (2011) Use of bisphosphonates and reduced risk of colorectal cancer. J Clin Oncol 29(9):1146–1150PubMedCrossRefGoogle Scholar
  16. 16.
    Green J, Czanner G, Reeves G et al (2010) Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case–control analysis within a UK primary care cohort. BMJ 341:4444CrossRefGoogle Scholar
  17. 17.
    Cardwell CR, Abnet CC, Cantwell MM, Murray LJ (2010) Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA 304:657–663PubMedCrossRefGoogle Scholar
  18. 18.
    Clézardin P, Ebetino FH, Fournier PG (2005) Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Res 65:4971–4974PubMedCrossRefGoogle Scholar
  19. 19.
    Guenther A, Gordon S, Tiemann M et al (2010) The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation. Int J Cancer 126:239–246PubMedCrossRefGoogle Scholar
  20. 20.
    Walker K, Olson MF (2005) Targeting Ras and Rho GTPases as opportunities for cancer therapeutics. Curr Opin Genet Dev 15:62–68PubMedCrossRefGoogle Scholar
  21. 21.
    (2010) Statins lose prevention ground. Nat Rev Cancer 10:385Google Scholar
  22. 22.
    Bertagnolli MM, Hsu M, Hawk ET, Eagle CJ, Zauber AG (2010) Adenoma Prevention with Celecoxib (APC) Study Investigators. Statin use and colorectal adenoma risk: results from the adenoma prevention with celecoxib trial. Cancer Prev Res (Phila Pa) 3:588–596CrossRefGoogle Scholar
  23. 23.
    Dietz HC (2010) New therapeutic approaches to Mendelian disorders. N Engl J Med 363:852–863PubMedCrossRefGoogle Scholar
  24. 24.
    Varela I, Pereira S, Ugalde AP et al (2008) Combined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging. Nat Med 14:767–772PubMedCrossRefGoogle Scholar
  25. 25.
    Pavli P, Maxwell L, van de Pol E, Doe WF (1995) Distribution of human colonic dendritic cells and macrophages—functional implications. Adv Exp Med Biol 378:121–123PubMedCrossRefGoogle Scholar
  26. 26.
    Coffelt SB, Hughes R, Lewis CE (2009) Tumor-associated macrophages: effectors of angiogenesis and tumor progression. Biochim Biophys Acta 1796:11–18PubMedGoogle Scholar
  27. 27.
    Jedinak A, Dudhgaonkar S, Sliva D (2010) Activated macrophages induce metastatic behavior of colon cancer cells. Immunobiology 215:242–249PubMedCrossRefGoogle Scholar
  28. 28.
    Roelofs AJ, Coxon FP, Ebetino FH et al (2010) Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo. J Bone Miner Res 25:606–616PubMedCrossRefGoogle Scholar
  29. 29.
    Grimm MC, Pavli P, Van de Pol E, Doe WF (1995) Evidence for a CD14+ population of monocytes in inflammatory bowel disease mucosa—implications for pathogenesis. Clin Exp Immunol 100:291–297PubMedCrossRefGoogle Scholar
  30. 30.
    Ballester I, Daddaoua A, López-Posadas R et al (2007) The bisphosphonate alendronate improves the damage associated with trinitrobenzenesulfonic acid-induced colitis in rats. Br J Pharmacol 151:206–215PubMedCrossRefGoogle Scholar
  31. 31.
    Sassa S, Okabe H, Nemoto N et al (2009) Icadronate may prevent colorectal carcinogenesis in mice with ulcerative colitis. Anticancer Res 29:4615–4619PubMedGoogle Scholar
  32. 32.
    Roelofs AJ, Jauhiainen M, Mönkkönen H et al (2009) Peripheral blood monocytes are responsible for γδ T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. Br J Haematol 144:245–250PubMedCrossRefGoogle Scholar
  33. 33.
    Benzaid I, Clezardin P (2010) Nitrogen-containing bisphosphonates and human gammadelta T cells IBMS BoneKEy 7: 208-217. http://www.bonekey-ibms.org/cgi/content/full/ibmske
  34. 34.
    Kunzmann V, Wilhelm M (2005) Anti-lymphoma effect of gammadelta T cells. Leuk Lymphoma 46:671–680PubMedCrossRefGoogle Scholar
  35. 35.
    Wang D, Dubois RN (2010) Eicosanoids and cancer. Nat Rev Cancer 10:181–193PubMedCrossRefGoogle Scholar
  36. 36.
    Eberhart CE, Coffey RJ, Radhika A et al (1994) Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107:1183–1188PubMedGoogle Scholar
  37. 37.
    Sheehan KM, Sabah M, Cummins RJ et al (2003) Cyclooxygenase-2 expression in stromal tumors of the gastrointestinal tract. Hum Pathol 34:1242–1246PubMedCrossRefGoogle Scholar
  38. 38.
    Liu ES, Shin VY, Ye YN et al (2005) Cyclooxygenase-2 in cancer cells and macrophages induces colon cancer cell growth by cigarette smoke extract. Eur J Pharmacol 518:47–55PubMedCrossRefGoogle Scholar
  39. 39.
    Cuzick J, Otto F, Baron JA et al (2009) Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 10:501–507PubMedCrossRefGoogle Scholar
  40. 40.
    Chan AT, Ogino S, Fuchs CS (2007) Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 356:2131–2142PubMedCrossRefGoogle Scholar
  41. 41.
    Rothwell PM, Wilson M, Elwin C et al (2010) Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 376:1741–1750PubMedCrossRefGoogle Scholar
  42. 42.
    Pazianas M, Abrahamsen B (2011) Safety of bisphosphonates. Bone 49(1):103–110, Epub 2011 Jan 12PubMedCrossRefGoogle Scholar
  43. 43.
    Abrahamsen B, Pazianas M, Eiken P, Russell RG, Eastell R (2011) Esophageal and gastric cancer incidence and mortality in alendronate users. J Bone Miner Res. doi: 10.1002/jbmr.1481 [Epub ahead of print]
  44. 44.
    Solomon DH, Patrick A, Brookhart MA (2009) More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 360:1789–1790PubMedCrossRefGoogle Scholar
  45. 45.
    Pazianas M, Russell RGG (2011) Potential therapeutic effects of oral bisphosphonates on the intestine. Ann N Y Acad Sci. [Epub ahead of print]Google Scholar
  46. 46.
    Manson JE, Mayne ST, Clinton SK (2011) Vitamin D and prevention of cancer—ready for prime time? N Engl J Med 364(15):1385–1387PubMedCrossRefGoogle Scholar
  47. 47.
    Fleisch H, Russell RG, Francis MD (1969) Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 165(899):1262–1264PubMedCrossRefGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2012

Authors and Affiliations

  • M. Pazianas
    • 1
    • 6
  • B. Abrahamsen
    • 2
    • 3
  • P. A. Eiken
    • 4
  • R. Eastell
    • 5
  • R. Graham G. Russell
    • 1
    • 5
  1. 1.The Botnar Research Centre and Oxford University Institute of Musculoskeletal Sciences, Department of Orthopaedics, Rheumatology & Musculoskeletal SciencesOxford UniversityOxfordUK
  2. 2.Department of Medicine FGentofte HospitalCopenhagenDenmark
  3. 3.OPEN, Institute of Clinical ResearchUniversity of Southern DenmarkOdenseDenmark
  4. 4.Department of Endocrinology & CardiologyHillerød HospitalHillerødDenmark
  5. 5.NIHR Bone Biomedical Research Unit and The Mellanby Centre for Bone ResearchUniversity of SheffieldSheffieldUK
  6. 6.Oxford University Institute of Musculoskeletal Sciences, Botnar Research Centre, Nuffield Orthopaedic CentreOxfordUK

Personalised recommendations